What is the clinical evidence from this study?

Study design: Cohort. Population: Venous thromboembolism (n=540). Intervention: Clinical predictive score. Primary outcome: New cancer diagnosis during one year of follow-up (score validation AUC) (AUC 0.79, 95% CI 0.63-0.95).

What does this research mean for the field?

A clinical predictive score incorporating previous VTE, recent surgery, and comorbidities accurately estimates the one-year risk of developing cancer following newly diagnosed venous thromboembolism. Novelty: ClaimNovelty.METHODOLOGICAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

July 22, 2013BMC CancerOpen Access

Predictive score for estimating cancer after venous thromboembolism: a cohort study

View Full Paper

Ask AI

Bookmark

Key result

Clinical score accurately predicts one-year cancer risk after newly diagnosed VTE with 0.79 AUC.

AUC 0.79
95% CI 0.63-0.95
n=540

Why the study?

Does a clinical predictive score accurately estimate the risk of developing cancer or death in adult patients following newly diagnosed VTE?

Population

540 adult patients with newly diagnosed venous thromboembolism, excluding those with previous or incident…

Design

Cohort

Follow-up

one year

Authors

BFBruno L. Ferreyro FAFederico Angriman DGDiego Giunta

Discussion

Member takes

Overview

May aid VTE risk stratification for surveillance; leaves open external validation and outcome impact.

Study Design

Type

Cohort (n=540)

Multicenter

Structured PICO

Does a clinical predictive score accurately estimate the risk of developing cancer or death in adult patients following newly diagnosed VTE?

Population

540 adult patients with newly diagnosed venous thromboembolism, free of prior cancer, followed for one year to develop and validate a predictive score for subsequent cancer or death.

Exposure

Clinical predictive score for cancer alone (including previous episode of VTE, recent surgery, and Charlson comorbidity score) and for cancer or death (including age, albumin level, comorbidity, previous episode of VTE, and recent surgery).

Outcome

New cancer diagnosis during one year of follow-uphard clinical

Main Result

Effect estimate: AUC 0.79 (95% CI 0.63-0.95)

A simple clinical predictive score using baseline variables accurately estimates the 1-year risk of developing cancer or death following a newly diagnosed VTE.

Limitations

Could only evaluate variables contained in the database
Included only baseline variables, unable to evaluate characteristics that evolve over time
Validation cohort was derived from the initial sample and was not an independent cohort
Lack of standardized cancer screening may have introduced bias
Evaluated only variables contained in the database
Lack of standardized cancer screening, making it possible that the study is biased by physicians' decisions

Cite This Study

Ferreyro et al. (2013) conducted a cohort in Venous thromboembolism (n=540). Clinical predictive score was evaluated on New cancer diagnosis during one year of follow-up (score validation AUC) (AUC 0.79, 95% CI 0.63-0.95). A clinical predictive score incorporating previous VTE, recent surgery, and comorbidities accurately estimated the one-year risk of developing cancer after newly diagnosed VTE, with an AUC of 0.79 in the validation cohort.

synapsesocial.com/papers/6aa67bc650dab972bddd696c https://doi.org/10.1186/1471-2407-13-352

View Full Paper

Ask AI

Bookmark

July 22, 2013BMC CancerOpen Access

Predictive score for estimating cancer after venous thromboembolism: a cohort study

View Full Paper

Ask AI

Bookmark

Key result

Clinical score accurately predicts one-year cancer risk after newly diagnosed VTE with 0.79 AUC.

AUC 0.79
95% CI 0.63-0.95
n=540

Why the study?

Does a clinical predictive score accurately estimate the risk of developing cancer or death in adult patients following newly diagnosed VTE?

Population

540 adult patients with newly diagnosed venous thromboembolism, excluding those with previous or incident…

Design

Cohort

Follow-up

one year

Authors

BFBruno L. Ferreyro FAFederico Angriman DGDiego Giunta

Discussion

Member takes

Overview

May aid VTE risk stratification for surveillance; leaves open external validation and outcome impact.

Study Design

Type

Cohort (n=540)

Multicenter

Structured PICO

Does a clinical predictive score accurately estimate the risk of developing cancer or death in adult patients following newly diagnosed VTE?

Population

540 adult patients with newly diagnosed venous thromboembolism, free of prior cancer, followed for one year to develop and validate a predictive score for subsequent cancer or death.

Exposure

Outcome

New cancer diagnosis during one year of follow-uphard clinical

Main Result

Effect estimate: AUC 0.79 (95% CI 0.63-0.95)

A simple clinical predictive score using baseline variables accurately estimates the 1-year risk of developing cancer or death following a newly diagnosed VTE.

Limitations

Could only evaluate variables contained in the database
Included only baseline variables, unable to evaluate characteristics that evolve over time
Validation cohort was derived from the initial sample and was not an independent cohort
Lack of standardized cancer screening may have introduced bias
Evaluated only variables contained in the database
Lack of standardized cancer screening, making it possible that the study is biased by physicians' decisions

Cite This Study

synapsesocial.com/papers/6aa67bc650dab972bddd696c https://doi.org/10.1186/1471-2407-13-352

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark